Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults |
| |
| Institution: | 1. Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield, WI 54449, USA;2. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA;3. Division of Viral Diseases, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA;1. Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;2. Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan;3. Department of Gastroenterological Oncology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan;4. Innovative Clinical Research Center, Kanazawa University, Ishikawa, Japan;5. Department of General Surgery, St. Luke’s International Hospital, Tokyo, Japan;6. Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;7. Medical Oncology Division, Kyoto Medical Center, Kyoto, Japan;8. Division of Gastroenterology, Saiseikai Utsunomiya Hospital, Tochigi, Japan;9. Department of Oncology, Yokohama Rosai Hospital, Kanagawa, Japan;10. Department of Gastroenterology, Toyama University Hospital, Toyama, Japan;11. Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan;1. Division of Pediatric Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI, USA;2. Division of Vaccine-Preventable Disease Control and National Immunization Program, Korea Centers for Disease Control and Prevention, Osong, Republic of Korea;3. Department of Family Medicine, Seoul National University College of Medicine, Republic of Korea;4. JW Lee Center for Global Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;1. Department of Orthopedic Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan;2. Department of Bone and Joint Biomaterial Research, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan;3. Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan;1. Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands;2. Department of Viroscience, Erasmus University Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands;3. Department of Medical Microbiology, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands;1. Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 1-12 Leninskie Gory, Moscow, 119234, Russian Federation;2. Group of Molecular Biotechnology, Federal State Institution «Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences», Leninsky pr., 33, Moscow, 119071, Russian Federation;1. Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands;2. Laboratory Medical Microbiology, Tergooi Hospital, Hilversum, The Netherlands;3. Department of Medical Microbiology, Bronovo Hospital, The Hague, The Netherlands;4. Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands;5. Department of Viroscience, Erasmus University MC, Rotterdam, The Netherlands |
| |
| Abstract: | BackgroundThird doses of measles-mumps-rubella (MMR) vaccine have been administered during mumps outbreaks and in various non-outbreak settings. The immunogenicity of the rubella component has not been evaluated following receipt of a third dose of MMR vaccine.MethodsYoung adults aged 18–31 years with documented two doses of MMR vaccine received a third dose of MMR vaccine between July 2009 and October 2010. Rubella neutralizing antibody titers were assessed before, 1 month, and 1 year after receipt of a third dose of MMR vaccine.ResultsAmong 679 participants, 1.8% had rubella antibody titers less than 10 U/ml, immediately before vaccination, approximately 15 years after receipt of a second dose of MMR vaccine. One month after receipt of a third dose of MMR vaccine, average titers were 4.5 times higher and >50% of participants had a 4-fold boost. Response was highest among those with titers less than 10 U/ml prior to vaccination (geometric mean titer ratio = 18.8; 92% seroconversion) and decreased with increasing pre-vaccination titers. Average titers declined 1 year postvaccination but remained significantly higher than pre-vaccination levels. The proportion classified as low-positive antibody levels increased from 3% 1 month postvaccination to 24% 1 year postvaccination.ConclusionsVaccination with a third dose of MMR vaccine resulted in a robust boosting of rubella neutralizing antibody response that remained elevated 1 year later. Young adults with low rubella titers are more likely to benefit from a third dose of MMR vaccine. |
| |
| Keywords: | Rubella Third-dose measles-mumps-rubella (MMR) vaccine Immune response |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
